Expression of angiogenic mediators in a patient with a retinal artery occlusion

Can J Ophthalmol. 2017 Aug;52(4):e122-e125. doi: 10.1016/j.jcjo.2017.01.010. Epub 2017 Mar 23.

Authors

Savalan Babapoor-Farrokhran¹, David Poon¹, Sharon Solomon¹, Silvia Montaner², Akrit Sodhi³

Affiliations

¹ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Department of Oncology and Diagnostic Sciences, School of Dentistry, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland; Department of Pathology, School of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
³ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: asodhi1@jhmi.edu.

PMID: 28774531
DOI: 10.1016/j.jcjo.2017.01.010

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiopoietin-2 / biosynthesis*
Angiopoietin-Like Protein 4 / metabolism*
Bevacizumab / administration & dosage*
Biomarkers / metabolism
Enzyme-Linked Immunosorbent Assay
Erythropoietin / biosynthesis*
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Male
Middle Aged
Retinal Artery / pathology
Retinal Artery Occlusion / diagnosis
Retinal Artery Occlusion / metabolism*
Retinal Artery Occlusion / physiopathology
Time Factors
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vascular Endothelial Growth Factor A / biosynthesis*
Visual Acuity
Vitreous Body / metabolism*

Substances

ANGPT2 protein, human
ANGPTL4 protein, human
Angiogenesis Inhibitors
Angiopoietin-2
Angiopoietin-Like Protein 4
Biomarkers
Vascular Endothelial Growth Factor A
Erythropoietin
Bevacizumab

Grants and funding

R01 EY025705/EY/NEI NIH HHS/United States